Consolidated Balance Sheets $ in Thousands	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Current assets:
Cash and cash equivalents	$ 9,825	$ 6,602
Restricted cash	6	4
Prepaid expenses and other current assets	508	177
Total current assets	10,339	6,783
Property, equipment and leasehold improvements, net	82	73
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,072	1,211
Prepaid clinical trial expenses	1,122	1,122
Other assets	17	26
Total assets	12,742	9,325
Current liabilities:
Accounts payable	518	942
Operating lease liabilities	310	294
Accrued expenses	964	1,427
Total current liabilities	1,792	2,663
Other liabilities	59	59
Operating lease liabilities - non current	861	1,020
Total liabilities	2,712	3,742
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 16,666,667 shares; 4,882,420 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at June 30, 2020; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019	2	2
Additional paid-in capital	233,791	224,741
Accumulated deficit	(223,763)	(219,160)
Total stockholders’ equity	10,030	5,583
Total liabilities and stockholders’ equity	$ 12,742	$ 9,325